Johnson & Johnson Operating Income 2010-2024 | JNJ

Johnson & Johnson annual/quarterly operating income history and growth rate from 2010 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
  • Johnson & Johnson operating income for the quarter ending March 31, 2024 was $3.714B, a 388.58% decline year-over-year.
  • Johnson & Johnson operating income for the twelve months ending March 31, 2024 was $20.063B, a 64.32% increase year-over-year.
  • Johnson & Johnson annual operating income for 2023 was $15.062B, a 22.2% decline from 2022.
  • Johnson & Johnson annual operating income for 2022 was $19.359B, a 0.94% increase from 2021.
  • Johnson & Johnson annual operating income for 2021 was $19.178B, a 16.25% increase from 2020.
Johnson & Johnson Annual Operating Income
(Millions of US $)
2023 $15,062
2022 $19,359
2021 $19,178
2020 $16,497
2019 $17,328
2018 $17,999
2017 $17,673
2016 $19,803
2015 $19,196
2014 $20,563
2013 $15,471
2012 $13,775
2011 $12,361
2010 $16,947
2009 $15,755
Johnson & Johnson Quarterly Operating Income
(Millions of US $)
2024-03-31 $3,714
2023-12-31 $4,370
2023-09-30 $5,217
2023-06-30 $6,762
2023-03-31 $-1,287
2022-12-31 $2,485
2022-09-30 $5,172
2022-06-30 $5,840
2022-03-31 $5,862
2021-12-31 $1,238
2021-09-30 $3,849
2021-06-30 $6,662
2021-03-31 $7,429
2020-12-31 $1,647
2020-09-30 $4,401
2020-06-30 $3,940
2020-03-31 $6,509
2019-12-31 $4,218
2019-09-30 $1,647
2019-06-30 $7,041
2019-03-31 $4,422
2018-12-31 $3,122
2018-09-30 $4,423
2018-06-30 $4,973
2018-03-31 $5,481
2017-12-31 $2,560
2017-09-30 $4,790
2017-06-30 $4,748
2017-03-31 $5,575
2016-12-31 $4,324
2016-09-30 $5,281
2016-06-30 $4,904
2016-03-31 $5,294
2015-12-31 $3,758
2015-09-30 $4,122
2015-06-30 $5,741
2015-03-31 $5,575
2014-12-31 $2,703
2014-09-30 $6,810
2014-06-30 $5,626
2014-03-31 $5,424
2013-12-31 $2,750
2013-09-30 $3,667
2013-06-30 $4,793
2013-03-31 $4,261
2012-12-31 $3,100
2012-09-30 $3,595
2012-06-30 $2,035
2012-03-31 $5,045
2011-12-31 $318
2011-09-30 $4,111
2011-06-30 $3,422
2011-03-31 $4,510
2010-12-31 $2,228
2010-09-30 $4,219
2010-06-30 $4,220
2010-03-31 $6,280
2009-12-31 $2,604
2009-09-30 $4,245
2009-06-30 $4,263
2009-03-31 $4,643
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $372.169B $85.159B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $731.812B 105.77
Novo Nordisk (NVO) Denmark $591.861B 45.48
Merck (MRK) United States $332.279B 60.46
AbbVie (ABBV) United States $293.876B 15.18
AstraZeneca (AZN) United Kingdom $238.424B 20.73
Novartis AG (NVS) Switzerland $209.653B 14.86
Pfizer (PFE) United States $162.291B 20.17
Sanofi (SNY) $123.116B 11.62
Innoviva (INVA) United States $0.998B 7.01